Land: Irland
Sprache: Englisch
Quelle: HPRA (Health Products Regulatory Authority)
Canine distemper virus strain N-CDV (live, attenuated); Canine adenovirus type 2 virus, strain manhattan (live, attenuated); Canine parainfluenza type 5 virus, strain NL-CPI-5 (live, attenuated); Canine parvovirus strain NL-35-D (live, attenuated); Leptospira canicola inactivated ; Leptospira icterohaemorrhagiae inactivated
Zoetis Belgium S.A.
QI07AI02
Canine distemper virus strain N-CDV (live, attenuated); Canine adenovirus type 2 virus, strain manhattan (live, attenuated); Canine parainfluenza type 5 virus, strain NL-CPI-5 (live, attenuated); Canine parvovirus strain NL-35-D (live, attenuated); Leptospira canicola inactivated ; Leptospira icterohaemorrhagiae inactivated
.
Lyophilisate and solvent for solution for injection
POM: Prescription Only Medicine as defined in relevant national legislation
Dogs
live canine distemper virus + live canine adenovirus + live canine parainfluenza virus + live canine parvovirus + inactivated leptospira
Immunological - Mixed Vaccine (L & A)
Authorised
2014-09-12
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Vanguard 7 lyophilisate and solvent for solution for injection for dogs 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each 1 ml dose contains: ACTIVE SUBSTANCES: Freeze dried fraction: Vanguard DA 2 Pi Canine distemper virus, strain N-CDV (live attenuated) minimum titre: 10 3.0 CCID 50 * Canine adenovirus Type 2, strain Manhattan (live attenuated) minimum titre: 10 3.2 CCID 50 * Canine parainfluenza virus, strain NL-CPI-5 (live attenuated) minimum titre: 10 6.0 CCID 50 * Liquid fraction: Vanguard CPV-L Canine Parvovirus, strain NL-35-D, low passage (live attenuated) minimum titre : 10 7.0 CCID 50 * _Leptospira canicola _ (inactivated) between 420 and 740 RU**/dose _Leptospira icterohaemorrhagiae _ (inactivated) between 463 to 915 RU**/dose *Cell culture infectious dose- 50 ** Relative units EXCIPIENTS: QUALITATIVE COMPOSITION OF EXCIPIENTS AND OTHER CONSTITUENTS Modified Eagles medium Dextran 40 Casein hydrolysate Lactose Sorbitol 70% (solution) Sodium hydroxide Water for Injection Freeze-dried: lightly colored pellets. Liquid: pinkish pink, transparent to slightly cloudy. 3. CLINICAL INFORMATION 3.1 TARGET SPECIES Dogs from 6 weeks of age. 3.2 INDICATIONS FOR USE FOR EACH TARGET SPECIES Active immunisation of dogs to prevent clinical signs of disease and reduce infection caused by canine adenovirus Type 2, to prevent mortality and clinical signs including leucopenia and reduce viral shedding caused by canine parvovirus (types 2a, 2b and 2c), to prevent clinical signs of disease caused by canine distemper virus and canine adenovirus Type 1, to reduce pathological signs of disease caused by parainfluenzavirus and to reduce infection caused by _Leptospira canicola_ and _Leptospira _ _icterohaemorrhagiae_ . Onset of immunity: 2 weeks after the last dose of the Basic Vaccination Scheme. 7 days after a single dose when animals are vaccinated from 9 weeks of age for the canine parvovirus component (type 2b ) Duration of immunity: 12 mo Lesen Sie das vollständige Dokument